ATL1103: Additional Phase II data

An open-label, European and Australian Phase II trial in 26 acromegalic patients showed that 200 mg ATL1103 given 3 times in week 1 followed by twice-weekly 200 mg ATL1103 for 12 weeks met the primary endpoint of reducing mean serum IGF-1 levels at week 14 compared to baseline (26% reduction from baseline, p<0.0001). All 13 patients in the twice-weekly arm had a reduction in serum IGF-1 levels from baseline to week 14. Antisense said the 200 mg ATL1103 given 3 times in week 1 followed by once-weekly 200 mg ATL1103 regimen missed the endpoint. In the once-weekly arm, 4 of 13 patients had a >20% reduction in serum IGF-1 levels. In January, the company reported interim data from the first 8 patients in the trial showing that ATL1103 was well tolerated (see BioCentury, Jan. 27). ...